WO2020101597A3 - Capsule compositions comprising tyrosine-kinase inhibitors - Google Patents

Capsule compositions comprising tyrosine-kinase inhibitors Download PDF

Info

Publication number
WO2020101597A3
WO2020101597A3 PCT/TR2019/050581 TR2019050581W WO2020101597A3 WO 2020101597 A3 WO2020101597 A3 WO 2020101597A3 TR 2019050581 W TR2019050581 W TR 2019050581W WO 2020101597 A3 WO2020101597 A3 WO 2020101597A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine
kinase inhibitors
capsule compositions
compositions
capsule
Prior art date
Application number
PCT/TR2019/050581
Other languages
French (fr)
Other versions
WO2020101597A2 (en
Inventor
Ali Ihsan SECKIN
Yuksel TOPALOGLU
Irem Yenice
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020101597A2 publication Critical patent/WO2020101597A2/en
Publication of WO2020101597A3 publication Critical patent/WO2020101597A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to solid oral pharmaceutical compositions comprising at least one tyrosine-kinase inhibitor (TKI), particularly nilotinib, or a pharmaceutically acceptable salt thereof providing high stability, solubility and patient compliance.
PCT/TR2019/050581 2018-08-27 2019-07-16 Capsule compositions comprising tyrosine-kinase inhibitors WO2020101597A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/12177 2018-08-27
TR201812177 2018-08-27

Publications (2)

Publication Number Publication Date
WO2020101597A2 WO2020101597A2 (en) 2020-05-22
WO2020101597A3 true WO2020101597A3 (en) 2020-07-02

Family

ID=70730583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050581 WO2020101597A2 (en) 2018-08-27 2019-07-16 Capsule compositions comprising tyrosine-kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2020101597A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174082A1 (en) * 2011-06-14 2012-12-20 Novartis Ag Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
WO2017158625A1 (en) * 2016-03-17 2017-09-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174082A1 (en) * 2011-06-14 2012-12-20 Novartis Ag Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
WO2017158625A1 (en) * 2016-03-17 2017-09-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib

Also Published As

Publication number Publication date
WO2020101597A2 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
PH12020550238A1 (en) Methods for the administration of certain vmat2 inhibitors
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2021002981A (en) Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors.
MY162494A (en) Solid pharmaceutical compositions containing an integrase inhibitor
MX2021006884A (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY.
MX2020007552A (en) Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate.
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
SA519410865B1 (en) Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
JOP20170197B1 (en) The novel formulation comprising a benzimidazole derivative
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
WO2020101597A3 (en) Capsule compositions comprising tyrosine-kinase inhibitors
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
MX2022000968A (en) Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate.
WO2019016673A3 (en) A stable oral pharmaceutical composition of imatinib
EA201991007A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS BASED ON LURAZIDONE HYDROCHLORIDE FOR ORAL USE
PH12016502527A1 (en) Stabilized desmopressin
WO2022146355A3 (en) Pharmaceutical capsule compositions of alogliptine
WO2020018034A3 (en) Oral pharmaceutical compositions comprising dpp-4 inhibitor
MX2021016044A (en) Dichlorphenamide compositions and methods of use.
JOP20170198A1 (en) Pharmaceutical formulations comprising tenofovir and emtricitabine
MX2021014830A (en) CONJUGATES OF <i>π</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS.
WO2019151966A3 (en) Pharmaceutical tablet compositions of dabigatran

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19883718

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19883718

Country of ref document: EP

Kind code of ref document: A2